The company was established in Asia in Malaysia. The main department of described VC is located in the Kuala Lumpur.
Considering the real fund results, this VC is 26 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Xeraya Capital works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2018.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight ViewRay, Acutus Medical, Rapid Micro Biosystems. Among the most popular fund investment industries, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups.
The overall number of key employees were 1.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Xeraya Capital, startups are often financed by OrbiMed, Khosla Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are OrbiMed, OUP (Osage University Partners), Kearny Venture Partners. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Deerfield Capital Management.
|Berggruen Holdings||New York, New York, United States|
|Cascade Investment Fund||-|
|Good Capital||New York, Tarrytown, United States|
|Haida Lianchuang Wuhan Touzi||China, Hubei, Wuhan|
|Linden Asset Management||Pennsylvania, Philadelphia, United States|
|Omaha Capital||Nebraska, Omaha, United States|
|Plum Alley||New York, New York, United States|
|Road Ventures||Geneva, Geneve, Switzerland|
|$125M||03 Feb 2022||Massachusetts, United States|
|$50M||09 Dec 2021||Phoenix, Arizona, United States|
|$50M||08 Dec 2021||Tempe, Arizona, United States|
|$80M||19 Nov 2020||California, United States|
|$34M||16 Nov 2020||South San Francisco, California, United States|
|$50M||09 Nov 2020||Cambridge, England, United Kingdom|
Rapid Micro Biosystems
|$120M||20 May 2020||Massachusetts, United States|
|$17M||12 May 2020||Massachusetts, United States|
|$31M||25 Feb 2020||Saint Paul, Minnesota, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.